Adjuvant and Neoadjuvant Therapy, Treatment for Advanced Disease, and Genetic Considerations for Adrenocortical Carcinoma: An Update from the SSO Endocrine and Head and Neck Disease Site Working Group. Ann Surg Oncol 2018 Nov;25(12):3453-3459
Date
09/16/2018Pubmed ID
30218246DOI
10.1245/s10434-018-6750-9Scopus ID
2-s2.0-85053445529 (requires institutional sign-in at Scopus site) 11 CitationsAbstract
This is the second of a two-part review on adrenocortical carcinoma (ACC) management. While margin-negative resection provides the only potential cure for ACC, recurrence rates remain high. Furthermore, many patients present with locally advanced, unresectable tumors and/or diffuse metastases. As a result, selecting patients for adjuvant therapy and understanding systemic therapy options for advanced ACC is important. Herein, we detail the current literature supporting the use of adjuvant mitotane therapy, consideration of adjuvant radiation therapy, and utility of cytotoxic chemotherapy in patients with advanced disease. Ongoing investigation into molecular targeted agents, immunotherapy, and inhibitors of steroidogenesis for the treatment of ACC are also highlighted. Lastly, the importance of genetic counseling in patients with ACC is addressed as up to 10% of patients will have an identifiable hereditary syndrome.
Author List
Dickson PV, Kim L, Yen TWF, Yang A, Grubbs EG, Patel D, Solórzano CCAuthor
Tina W F Yen MD, MS Professor in the Surgery department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Adrenal Gland NeoplasmsAdrenalectomy
Adrenocortical Carcinoma
Antineoplastic Combined Chemotherapy Protocols
Combined Modality Therapy
Genetic Counseling
Humans
Mitotane
Radiotherapy
